Prognosis of low-grade glioma based on the WWOX/HIF1A ratio requires consideration of the role of immunological pathways that influence the tumour microenvironment (Figure 25) and disease progression, and immunological risk assessment allows for effective differentiation of patients and identification of those who may benefit from aggressive treatment, e.g., radiotherapy. The gene discussed is HIF1A; the disease is neoplasm.